Mapping the Future: A Comprehensive Bibliometric Analysis of Circulating Tumor DNA in Colorectal Cancer

Overview

Journal J Multidiscip Healthc

Publisher Dove Medical Press

Specialty Health Services

Date 2024 Nov 27

PMID 39600714

Authors

Chengzu Wang

Affiliations

Soon will be listed here.

Abstract

Purpose: Colorectal cancer (CRC) is among the most prevalent malignancies worldwide, with rising incidence and mortality rates presenting substantial public health challenges. Traditional detection methods have inherent limitations, which has led to growing interest in liquid biopsy technologies for the identification of circulating tumor DNA (ctDNA). The aim of this study is to explore the developmental trends and future prospects of ctDNA in colorectal cancer through bibliometric analysis.

Methods: This bibliometric analysis examines the literature on ctDNA in CRC from 2004 to 2024, utilizing the Web of Science Core Collection database to identify research trends, key areas of interest, and potential future directions. The R package "bibliometrix" and VOSviewer software were employed for bibliometric analysis and visualization. The analysis encompassed an evaluation of publication volume, contributing authors, influential journals, country and institutional contributions, and citation metrics.

Results: The analysis encompassed a total of 1,054 publications, demonstrating a marked escalation in research activity since 2015. The journal "Cancers" has been identified as the most prolific publisher within this domain. Prominent researchers, including Bardelli A and Sartore-Bianchi A, have made substantial contributions to the field. The United States is the leading country in terms of both publication volume and citation frequency, followed by China and Italy. A keyword analysis identified seven conceptual clusters, with "circulating tumor DNA" and "liquid biopsy" emerging as predominant themes.

Conclusion: This study emphasizes the evolving emphasis on the clinical applications of ctDNA, encompassing early detection, treatment monitoring, and prognostic assessment in CRC, thereby underscoring its potential as a non-invasive biomarker in oncology.

References

Sefrioui D, Sarafan-Vasseur N, Beaussire L, Baretti M, Gangloff A, Blanchard F . Clinical value of chip-based digital-PCR platform for the detection of circulating DNA in metastatic colorectal cancer. Dig Liver Dis. 2015; 47(10):884-90. DOI: 10.1016/j.dld.2015.05.023. View

Naranan S . Bradford's law of bibliography of science: an interpretation. Nature. 1970; 227(5258):631-2. DOI: 10.1038/227631a0. View

Tao X, Li Q, Zeng Y . Clinical application of liquid biopsy in colorectal cancer: detection, prediction, and treatment monitoring. Mol Cancer. 2024; 23(1):145. PMC: 11250976. DOI: 10.1186/s12943-024-02063-2. View

Scholer L, Reinert T, Orntoft M, Kassentoft C, Arnadottir S, Vang S . Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer. Clin Cancer Res. 2017; 23(18):5437-5445. DOI: 10.1158/1078-0432.CCR-17-0510. View

van Eck N, Waltman L . Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010; 84(2):523-538. PMC: 2883932. DOI: 10.1007/s11192-009-0146-3. View

Schraa S, van Rooijen K, van der Kruijssen D, Rubio Alarcon C, Phallen J, Sausen M . Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study. BMC Cancer. 2020; 20(1):790. PMC: 7441668. DOI: 10.1186/s12885-020-07252-y. View

Luo H, Zhao Q, Wei W, Zheng L, Yi S, Li G . Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Sci Transl Med. 2020; 12(524). DOI: 10.1126/scitranslmed.aax7533. View

Xiong B, Huang Q, Zheng H, Lin S, Xu J . Recent advances microRNAs and metabolic reprogramming in colorectal cancer research. Front Oncol. 2023; 13:1165862. PMC: 10415904. DOI: 10.3389/fonc.2023.1165862. View

Nguyen V, Nguyen T, Doan N, Pham T, Nguyen G, Nguyen T . Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization. Elife. 2023; 12. PMC: 10567114. DOI: 10.7554/eLife.89083. View

10.

Perez-Carbonell L, Sinicrope F, Alberts S, Oberg A, Balaguer F, Castells A . MiR-320e is a novel prognostic biomarker in colorectal cancer. Br J Cancer. 2015; 113(1):83-90. PMC: 4647533. DOI: 10.1038/bjc.2015.168. View

11.

Sa R, Xu Y, Pan X, Wang Y, Lin Z, Zhang X . A bibliometric analysis of research progress on pharmacovigilance and cancer from 2002 to 2021. Front Oncol. 2023; 13:1078254. PMC: 9905820. DOI: 10.3389/fonc.2023.1078254. View

12.

Van Cutsem E, Cervantes A, Adam R, Sobrero A, van Krieken J, Aderka D . ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016; 27(8):1386-422. DOI: 10.1093/annonc/mdw235. View

13.

Imperiale T, Ransohoff D, Itzkowitz S . Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014; 371(2):187-8. DOI: 10.1056/NEJMc1405215. View

14.

Emiloju O, Storandt M, Zemla T, Tran N, Jethwa K, Mahipal A . Tumor-Informed Circulating Tumor DNA for Minimal Residual Disease Detection in the Management of Colorectal Cancer. JCO Precis Oncol. 2024; 8():e2300127. PMC: 10805428. DOI: 10.1200/PO.23.00127. View

15.

Hanna M, Dey N, Grady W . Emerging Tests for Noninvasive Colorectal Cancer Screening. Clin Gastroenterol Hepatol. 2022; 21(3):604-616. PMC: 9974876. DOI: 10.1016/j.cgh.2022.12.008. View

16.

Hibino Y, Sakamoto N, Naito Y, Goto K, Oo H, Sentani K . Significance of miR-148a in Colorectal Neoplasia: Downregulation of miR-148a Contributes to the Carcinogenesis and Cell Invasion of Colorectal Cancer. Pathobiology. 2015; 82(5):233-41. DOI: 10.1159/000438826. View

17.

Shaukat A, Levin T . Current and future colorectal cancer screening strategies. Nat Rev Gastroenterol Hepatol. 2022; 19(8):521-531. PMC: 9063618. DOI: 10.1038/s41575-022-00612-y. View

18.

Bortoletto A, Parchem R . KRAS Hijacks the miRNA Regulatory Pathway in Cancer. Cancer Res. 2023; 83(10):1563-1572. PMC: 10183808. DOI: 10.1158/0008-5472.CAN-23-0296. View

19.

Lu Y, Zhao X, Liu Q, Li C, Graves-Deal R, Cao Z . lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/β-catenin signaling. Nat Med. 2017; 23(11):1331-1341. PMC: 5961502. DOI: 10.1038/nm.4424. View

20.

Rassy E, Parent P, Lefort F, Boussios S, Baciarello G, Pavlidis N . New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?. Crit Rev Oncol Hematol. 2020; 147:102882. DOI: 10.1016/j.critrevonc.2020.102882. View